Tag: Breast Cancer
Disruption of a single amino acid in a cellular protein makes breast cancer cells behave like stem cells
Changes to the intermediate filament (IF) protein, vimentin, were found to promote tumor growth by increasing cancer stemness in an oestrogen independent manner. Targeting vimentin and/or the long noncoding RNA (lncRNA) ‘XIST’ could be an effective therapeutic strategy for treating aggressive breast cancer.
[ASAP] Correction to “Enhancing the Antitumor Effect of Doxorubicin with Photosensitive Metal–Organic Framework Nanoparticles against Breast Cancer”
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.5c00049
[ASAP] Development and Preclinical Assessment of a Palbociclib Nanostructured Lipid Carrier for Potential Breast Cancer Management
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.4c01122
Community‐engaged adaptation of ACCESS: A navigator‐led early palliative care intervention for Black and Latina women with advanced breast cancer
Abstract Introduction Disparities in early palliative care (PC) access for Black and Latina women with advanced breast cancer (ABC) persist. This study elicited qualitative feedback from patients with ABC and health professionals to adapt a community navigator-led early PC program called ACCESS to improve PC access and supportive care outcomes for Black and Latina women… Continue reading Community‐engaged adaptation of ACCESS: A navigator‐led early palliative care intervention for Black and Latina women with advanced breast cancer
FOxTROT: is anti-EGFR a good dancing partner?
The introduction of neoadjuvant (pre-surgery) therapy represented a paradigm shift in the treatment approach of many localized solid tumors, such as rectal cancer, breast cancer and gastroesophageal tumors. The advantages of a neoadjuvant strategy are both local and systemic, including a potential shrinkage of the primary tumor and increased chances of a complete oncological surgery,… Continue reading FOxTROT: is anti-EGFR a good dancing partner?
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas
Patients with HER2-negative advanced-stage gastric or gastro-oesophageal junction (G/GEJ) adenocarcinomas typically receive chemotherapy with or without an anti-PD-1 antibody as first-line treatment. Now, data from the phase III COMPASSION-15 trial show that combination of the PD-1 × CTLA4 bispecific antibody cadonilimab plus chemotherapy is also efficacious in this setting. In this trial, conduced in China,… Continue reading Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas
[News] Law to extend free medical treatment for breast cancer in France
The French Parliament voted unanimously in favour of a law to expand free medical and supportive treatment for patients with breast cancer to items that cost an average of €1400 per case.
Fear of breast cancer recurrence: Impact and coping with being in a dark place
A new study of breast cancer survivors has found this psychosocial challenge impacts almost every important domain of their lives — the emotional, behavioral, cognitive, relational and professional. A larger number of domains was affected, and they were affected more frequently in those with greater fear of recurrence. The majority of study participants indicated that… Continue reading Fear of breast cancer recurrence: Impact and coping with being in a dark place
AACR Patient Advocate Forum: Patient-centric Cancer Clinical Trial Design
Before a new treatment becomes available for cancer patients, it must be tested in clinical trials and shown to be both safe for use and effective at treating the disease. But an explosion of new approaches to care, the rise of precision oncology that targets certain tumor mutations rather than broad cancer types, and low rates… Continue reading AACR Patient Advocate Forum: Patient-centric Cancer Clinical Trial Design